Addex Moves R&D Operations to Geneva’s Campus Biotech

Addex Moves R&D Operations to Geneva’s Campus Biotech

Geneva, Switzerland, December 7, 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today that it has moved its R&D operations to the Campus Biotech, a new life sciences center of excellence located at the former Merck Serono site in Geneva.

“We are delighted to welcome Addex to our center of excellence in life science. As a leader in allosteric modulator drug discovery which is ideally suited to neuroscience, Addex is perfectly aligned with our mission to build a center of excellence in life science and in particular neuroscience,” commented Dr. Benoît Dubuis, Director Campus Biotech and Development Director Wyss Center.

“Joining the center of excellence in life science and in particular neuroscience that is being created at the Campus Biotech will provide Addex with access to multiple cutting edge scientific platforms,” commented Tim Dyer CEO at Addex. “We believe being part of the Campus’s blend of science and industry, is the perfect environment for Addex to excel as we execute on our strategy to advance our portfolio of allosteric modulator drug candidates.”

About Campus Biotech
Campus Biotech is a new life sciences center of excellence located at the former Merck Serono site in Geneva. Campus Biotech creates new opportunities for scientists and entrepreneurs by providing a unique environment to translate ideas into products that will impact society and the world. Extending out over 40,000m2, this unique center of excellence in Europe welcomes many academic and industrial partners, of which, in particular, teams from EPFL (the Lausanne-based Swiss Federal Institute of Technology), UNIGE (University of Geneva), the University Hospitals of Geneva, the Wyss Centre of bio- and neuro-engineering, the Human Brain Project, the Swiss Institute of bioinformatics, and the HEPIA which is part of the HES-SO (University of Applied Sciences Western Switzerland). This new ecosystem is based on an interdisciplinary scientific approach to stimulating innovation in the area of life sciences. Its main objective is to concentrate on pure science and its transposition into products which will have a direct impact on society and on the world. Campus Biotech acts as a catalyst of a new surge and new investments in the essential sector of economics and science, and was established by a consortium made up of the EPFL, UNIGE, the Bertarelli family and HansJörg Wyss.    

About Addex Therapeutics
Addex Therapeutics ( is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase IIa POC in Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter Phase IIb/III for PD-LID. In parallel, dipraglurant’s therapeutic use in dystonia is being investigated. Addex second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for Epilepsy. Addex also has several preclinical programs including: ADX71441 (GABAB receptor PAM) which has received regulatory approval to start Phase I and is being investigated for therapeutic use in Charcot-Marie-Tooth (Type 1A) disease, alcohol use disorder and nicotine dependence; mGluR4PAM for drug abuse and dependence, Parkinson’s disease and other neurodegenerative diseases; mGluR2NAM for treatment resistant depression and cognitive deficits; mGluR7NAM for psychosomatic disorders, TrkBPAM for neurodegenerative disorders; and GLP1PAM for type 2 diabetes. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

Press Contacts:
Tim Dyer
Chief Executive Officer
Addex Therapeutics
Telephone: +41 22 884 15 61
Email: PR(at)

Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.